Insider filings
Summit Therapeutics Inc. (SMMT)
Free on iOS and Android.
About Summit Therapeutics Inc.
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Robert W. Duggan
- Employees
- 265
- Listed since
- Mar 5, 2015
- Market value
- $12.3B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$1.10
- Dividend yield
- -
Company news
3 articles · newest first| Headline | Source | Date |
|---|---|---|
| Summit Therapeutics to feature ivonescimab data at ESMO 2026The company said the data will be presented in numerous presentations across multiple tumor types at the congress in Madrid, Spain. | Company release | Oct 22, 2026 |
| Summit Therapeutics enters ivonescimab trial collaboration with ECOG-ACRINThe Phase II/III study evaluates ivonescimab, an investigational bispecific antibody, in first-line biliary tract cancer. | Company release | Oct 21, 2026 |
| Summit Therapeutics opens global Phase II ivonescimab study in kidney cancerThe multiregional study is testing ivonescimab-based regimens in patients who have not had prior treatment for their cancer. | Company release | Oct 19, 2026 |
Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover
Earnings
6 reported quarters · next on Oct 26, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 23, 2026 | -$0.28 | -$0.27 | n/a | $114K | EPS miss, GAAPRevenue n/a |
| Q1 FY2026reported Apr 30, 2026 | -$0.24 | -$0.33 | n/a | $54K | EPS beat, GAAPRevenue n/a |
| Q4 FY2025reported Feb 23, 2026 | -$0.29 | -$0.10 | n/a | n/a | EPS missRevenue n/a |
| Q3 FY2025reported Oct 20, 2025 | -$0.31 | -$0.18 | n/a | n/a | EPS miss, GAAPRevenue n/a |
| Q2 FY2025reported Aug 11, 2025 | -$0.76 | -$0.09 | n/a | n/a | EPS miss, GAAPRevenue n/a |
| Q1 FY2025reported May 1, 2025 | -$0.09 | -$0.09 | n/a | n/a | EPS beat, GAAPRevenue n/a |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A figure or flag reads n/a when a number is missing, or when the figure failed our check against the company's other quarters, its own filings and its share splits, and was left out. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 17, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Manmeet SoniChief Operating Officer, Chief Financial Officer and Director | $617K | $0 | $248.5M | $249.1M |
| Mahkam ZanganehCo-Chief Executive Officer, President and Director | $617K | $0 | $245.4M | $246.0M |
| Robert W. DugganCo-Chief Executive Officer and Chairman | $0 | $0 | $172K | $172K |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| Baker Bros. Advisors LP | $477.7M | 32,786,348 | -9.9% | 4.21% |
| FMR LLC | $146.3M | 10,043,947 | -7.5% | 1.29% |
| State Street Corp | $139.0M | 9,536,796 | +35.7% | 1.23% |
| BlackRock, Inc. | $138.8M | 9,529,041 | -1.3% | 1.22% |
| Vanguard Capital Management LLC | $83.6M | 5,734,484 | +0.4% | 0.74% |
| UBS Group AG | $76.3M | 5,233,798 | +42.2% | 0.67% |
| Vanguard Portfolio Management LLC | $73.5M | 5,042,190 | -3.7% | 0.65% |
| Goldman Sachs Group Inc | $65.8M | 4,513,399 | +1352.5% | 0.58% |
| T. Rowe Price Associates, Inc. | $56.7M | 3,893,820 | -53.0% | 0.50% |
| Point72 Asset Management, L.P.Steve Cohen | $53.9M | 3,697,803 | +371.5% | 0.48% |
| Geode Capital Management, LLC | $50.0M | 3,427,263 | +3.4% | 0.44% |
| Millennium Management LLC | $34.2M | 2,349,081 | +1760.3% | 0.30% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
15 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Robert W. DugganCo-Chief Executive Officer | Bought | 3,810,000 | $13.12 | $50.0M | Jun 12, 2026filed Jun 12, 2026 | 0d |
| Mahkam ZanganehCo-Chief Executive Officer | Bought | 3,810,000 | $13.12 | $50.0M | Jun 12, 2026filed Jun 12, 2026 | 0d |
| Manmeet Singh SoniCOO and CFO | Bought | 25,000 | $14.43 | $361K | Jun 4, 2026filed Jun 4, 2026 | 0d |
| Mahkam ZanganehCo-Chief Executive Officer | Bought | 100,000 | $14.60 | $1.5M | Jun 4, 2026filed Jun 4, 2026 | 0d |
| Robert W. DugganCo-Chief Executive Officer | Bought | 100,000 | $14.60 | $1.5M | Jun 4, 2026filed Jun 4, 2026 | 0d |
| Mahkam ZanganehCo-Chief Executive Officer | Bought | 26,680 | $18.74 | $500K | Oct 21, 2025filed Oct 23, 2025 | 2d |
| Robert W. DugganCo-Chief Executive Officer | Bought | 26,680 | $18.74 | $500K | Oct 21, 2025filed Oct 23, 2025 | 2d |
| Yu XiaDirector | Bought | 533,617 | $18.74 | $10.0M | Oct 21, 2025filed Oct 23, 2025 | 2d |
| Robert W. DugganCo-Chief Executive Officer | Bought | 333,394 | $17.68 | $5.9M | Sep 10, 2025filed Sep 11, 2025 | 1d |
| Robert W. DugganCo-Chief Executive Officer | Bought | 5,000 | $18.07 | $90K | Sep 11, 2025filed Sep 11, 2025 | 0d |
| Mahkam ZanganehCo-Chief Executive Officer | Bought | 333,394 | $17.68 | $5.9M | Sep 10, 2025filed Sep 11, 2025 | 1d |
| Mahkam ZanganehCo-Chief Executive Officer | Bought | 5,000 | $18.07 | $90K | Sep 11, 2025filed Sep 11, 2025 | 0d |
| Ankur DhingraChief Financial Officer | Bought | 100,000 | $3.75 | $375K | Mar 26, 2024filed Mar 27, 2024 | 1d |
| Mahkam ZanganehChief Executive Officer | Bought | 30,000 | $3.75 | $113K | Mar 26, 2024filed Mar 27, 2024 | 1d |
| Mahkam ZanganehChief Executive Officer | Bought · 2 lines | 46,000 | $3.72 | $171K | Mar 27, 2024filed Mar 27, 2024 | 0d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Bhaskar AnandChief Accounting Officer | Stock award | 100,000 | Oct 8, 2026 |
| Bhaskar AnandChief Accounting Officer | Stock award | 30,000 | Jan 8, 2026 |
| Alessandra CesanoDirector | Stock award | 38,219 | Jan 2, 2026 |
| Kenneth A. ClarkDirector | Stock award | 52,796 | Jan 2, 2026 |
| Mostafa RonaghiDirector | Stock award | 35,000 | Jan 2, 2026 |
| Jeff HuberDirector | Stock award | 44,885 | Jan 2, 2026 |
| Yu XiaDirector | Stock award | 35,000 | Jan 2, 2026 |
| Robert F. BoothDirector | Stock award | 42,180 | Jan 2, 2026 |
| Robert W. DugganCo-Chief Executive Officer | Stock award | 11,232 | Jan 2, 2026 |
| Mahkam ZanganehCo-Chief Executive Officer | Stock award | 11,232 | Jan 2, 2026 |
| Mahkam ZanganehCo-Chief Executive Officer | Stock award | 14,247,597 | Oct 21, 2025 |
| Robert W. DugganCo-Chief Executive Officer | Stock award | 14,247,597 | Oct 21, 2025 |
| Manmeet Singh SoniCOO and CFO | Stock award | 53,361 | Oct 21, 2025 |
| Bhaskar AnandChief Accounting Officer | Stock award | 26,680 | Oct 21, 2025 |
| Bhaskar AnandChief Accounting Officer | Stock award | 50,000 | Sep 18, 2025 |
| Robert W. DugganCo-Chief Executive Officer | Option exercise | 74,545 | May 30, 2025 |
| Mahkam ZanganehCo-Chief Executive Officer | Option exercise | 74,545 | May 30, 2025 |
| Mahkam ZanganehCo-Chief Executive Officer | Stock award | 11,030,558 | Apr 29, 2025 |
| Robert W. DugganCo-Chief Executive Officer | Stock award | 11,030,558 | Apr 29, 2025 |
| Manmeet Singh SoniCOO and CFO | Stock award | 11,200,000 | Apr 29, 2025 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling SMMT?
Across the 15 most recent open-market filings shown here, 15 were purchases and 0 were sales.
How quickly are SMMT trades disclosed?
Insider filings on this page reached the public a median of 0 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.